Get the Stockscreener App
16.22
1.37%
0.22
After Hours:
16.00
-0.22
-1.36%
Aurinia Pharmaceuticals Inc stock is traded at $16.22, with a volume of 1.37M.
It is up +1.37% in the last 24 hours and up +6.15% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$16.00
Open:
$16.08
24h Volume:
1.37M
Relative Volume:
1.17
Market Cap:
$2.09B
Revenue:
$298.30M
Net Income/Loss:
$298.21M
P/E Ratio:
7.4964
EPS:
2.1637
Net Cash Flow:
$166.93M
1W Performance:
+2.79%
1M Performance:
+6.15%
6M Performance:
+2.33%
1Y Performance:
+99.26%
1-Day Range:
$15.94
$16.33
1-Week Range:
$15.47
$16.33
52-Week Range:
$7.285
$16.88
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
16.22 | 2.06B | 298.30M | 298.21M | 166.93M | 2.1637 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Screens as Strong Candidate Based on Minervini Trend Template and High Growth Momentum Rating - ChartMill
13D Filings -- Barrons.com - Moomoo
A Fresh Look At Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Consolidation - Yahoo Finance
Aurinia (NASDAQ: AUPH) director receives grant of 23,931 stock options - Stock Titan
Aurinia (NASDAQ: AUPH) director awarded 23,931 stock options expiring 2036 - Stock Titan
Aurinia Pharmaceuticals (AUPH) director receives 23,931 share option grant - Stock Titan
Aurinia (AUPH) director Jeffrey Bailey granted 23,931 stock options at $15.67 - Stock Titan
Avoiding Lag: Real-Time Signals in (AUPH) Movement - Stock Traders Daily
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million - The Motley Fool
AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors - Stocktwits
TANG KEVIN C's Strategic Acquisition in Aurinia Pharmaceuticals Inc - GuruFocus
Insider sales, option exercise at AUPH (NASDAQ: AUPH) reported - Stock Titan
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Tang group discloses 10% Aurinia (AUPH) stake plus $15 put options - Stock Titan
Strong shareholder support for Aurinia (NASDAQ: AUPH) board, auditor and say-on-pay - Stock Titan
AUPH: 25,000-share option exercise filed; Keenan sold 25,000 on 06/02/2026 - Stock Titan
Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow (NASDAQ:AUPH) - Seeking Alpha
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death - Business Wire
AUPH stock rallies after CEO shake-up: Retail bulls bet on turnaround - MSN
Aurinia Pharmaceuticals Insider Bought Shares Worth $12,455,227, According to a Recent SEC Filing - Moomoo
Insider Stock Purchases: June 03, 2026 - Quiver Quantitative
Chief Executive Officer Of Aurinia Pharmaceuticals Makes $12.46M Buy - Benzinga
TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC. - Quantisnow
Funds tied to Aurinia Pharmaceuticals (AUPH) add shares, sell put options - Stock Titan
Aurinia Pharmaceuticals(AUPH.US) 10% Shareholder Buys US$12.46 Million in Common Stock - Moomoo
25,000-Share Sale Notice for AUPH (NASDAQ: AUPH) - Stock Titan
AUPH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aurinia Stock Dips as Traders Eye Lupkynis Data - Bez Kabli
AUPH Stock Price, Quote & Chart | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
Discipline and Rules-Based Execution in AUPH Response - Stock Traders Daily
AUPH News | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
Aurinia (AUPH) Chief Legal Officer granted 115,541 performance stock units - Stock Titan
Aurinia Pharmaceuticals (AUPH) grants PSUs and stock options to CFO - Stock Titan
Aurinia (AUPH) COO receives 116,144 PSUs and 70,230 stock options - Stock Titan
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences - citybiz
Tranche Update on Aurinia Pharmaceuticals Inc.'s Equity Buyback Plan announced on February 15, 2024. - marketscreener.com
Why Aurinia Pharmaceuticals stock is surging Monday morning - MSN
Tangible book value per share of Aurinia Pharmaceuticals Inc. – FWB:IKAP - TradingView
Aurinia Pharmaceuticals stock (CA05156H1070): Q1 revenue beat and July earnings date in focus - AD HOC NEWS
Jefferies Upgrades Aurinia Pharmaceuticals (AUPH) - MSN
Behavioral Patterns of AUPH and Institutional Flows - Stock Traders Daily
Aurinia Pharmaceuticals (AUPH) Price Target Increased by 34.15% to 16.03 - MSN
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Raises Some Questions - simplywall.st
We Believe Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings Are A Poor Guide For Its Profitability - Yahoo Finance
Kezar Life Sciences stock (US49374L1008): Merger with Aurinia completes, shares cancelled - AD HOC NEWS
Aurinia Pharmaceuticals IncCommon Shares (NQ: AUPH - FinancialContent
Aurinia deal leaves Kezar (KZR) wholly owned as Tang Capital exits - Stock Titan
Aurinia Pharmaceuticals stock (CA05156H1070): Announces $6.955 Cash Acquisition of Kezar Life Scienc - AD HOC NEWS
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):